Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Today’s trading

<< Previous

Bullboard Posts

Next >>

Comment by jeffm34on Feb 04, 2021 12:00pm

76 Views

Post# 32470778

RE:RE:RE:RE:RE:RE:Today’s trading

it's not grief we need to work through. It's trust in management that they will not continue to make the same mistakes over and over. They haven't learned yet.

SPCEO1 wrote: Still working through the stages of grief - it may be a while....

jfm1330 wrote: And I should add that I am not looking that bad either since I was the one who was enthusiatic here, early after the deal, about the potential of this acquisition.

Come on SPCEO, put a smile on your face for a second at least. I told you that the silver lining of all that was that they were now aiming at very big markets. What we lost in the dilution we may make it back and more the day the market will fully recognize the potential. It is frustrating to say, but Thera needed outside validation, and today they got it from no other than the FDA. The company will acquire credibility only with positive news on meaningful aspects like that and ultimately, with real success. They are no longer looking at niche markets where the drugs is hard to sell. An effective therapy for cancer is not hard to sell.

SPCEO1 wrote: I gotta say, Luc is looking smarter by the day. And I doubt he would have done that deal, at least on those atrocious terms.

jfm1330 wrote: Yes, his name is Paul Pommier and he is by far the biggest shareholder on the BOD and management of Thera and he bought some more in the last offering. Oh! And by the way, he is a good friend of Luc Tanguay. You know the guy who had the foresshight to buy Katana for a few millions two years ago...

Wino115 wrote: Interesting. Don't forget one of the Board members is also a past NBF guy. Guess they didn't convince them enough. This is where capitalizing on the news via a bit of PR would be helpful. Wonder if they understand that in the CFO office? Get going Dubuc...make up for your lack of contacts in finance by getting some PR on your side.

jeffm34 wrote: I see Dubuc's friends over at NBF are by far the biggest sellers so far this morning. So much for their claim the new investors are in it for the long term.